NCT07537738 Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
| NCT ID | NCT07537738 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University People's Hospital |
| Condition | Acute Myeloid Leukemia (AML) |
| Study Type | OBSERVATIONAL |
| Enrollment | 210 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-04-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 210 participants in total. It began in 2025-06-01 with a primary completion date of 2026-04-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is: • Could be leukemia stem cell used for relapse prediction in acute myeloid leukemia patients with MLL-rearrangement? Leukemia stem cell will be detected at the same time for participants who detected minimal residual disease using bone marrow as part of their regular medical care to answer the question.
Eligibility Criteria
Inclusion Criteria: Acute myeloiud leukemia patients with MLL arrangement aging 6-60 years recieving chemoterapy or allo-geneic hematopoietic stem cell transplantation. Exclusion Criteria: 1. Patients who cannot recieve chemoterapy or allo-geneic hematopoietic stem cell transplantation. 2. Patients who cannot comply with the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07537738 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 60 Years, studying Acute Myeloid Leukemia (AML). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07537738 currently recruiting?
Yes, NCT07537738 is actively recruiting participants. Contact the research team at tina_li_1995@163.com for enrollment information.
Where is the NCT07537738 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07537738 clinical trial?
NCT07537738 is sponsored by Peking University People's Hospital. The trial plans to enroll 210 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.